A USA-based registry for pulmonary arterial hypertension: 1982-2006

European Respiratory Journal

Volumn 30, Issue 6, 2007, Pages 1103-1110

  Thenappan, T ^a   Shah, S J ^a   Rich, S ^a   Gomberg Maitland, M ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC 2016 ^*  (United States)

Author keywords

Aetiology; Epidemiology; Medications; Pulmonary arterial hypertension; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; HEMODYNAMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SURVIVAL RATE; TERTIARY HEALTH CARE; TREATMENT RESPONSE; UNITED STATES; WORLD HEALTH ORGANIZATION;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PULMONARY ARTERY; REGISTRIES; SEX DISTRIBUTION; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 37549033243     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00042107     Document Type: Article

References (33)

1. Rich S, Dantzker R, Ayres S, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223.
2. D'Alonzo G, Barst R, Ayres S, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
4. Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
5. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1586-1589.
6. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
7. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
8. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.
9. Rubin L, Badesch D, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. N Eng J Med 2002; 346: 896-903.
10. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
11. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
12. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 1390-1395.
13. Humbert M. The burden of pulmonary hypertension. Eur Respir J 2007; 30: 1287-1288.
14. Rubin LJ, American College of Chest Physicians, Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl. 1, 4S-6S.
15. Patterson JA, Naughton J, Pietras RJ, Gunnar RM. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol 1972; 30: 757-762.
16. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
17. Nootens M, Schrader B, Kaufman E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995; 107: 54-57.
18. Barst RJ. Evaluation and treatment for angina in pulmonary arterial hypertension. Am J Med 2004; 116: 427-428.
19. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
20. Nunes H, Humbert M, Sitbon O, et al. Prognositc factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167: 1433-1439.
21. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest 2007; 131: 94-100.
22. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-3050.
23. Alkotob ML, Soltani P, Sheatt MA, et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest 2006; 130: 176-181.
24. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350.
25. Badesch D, Tapson V, McGoon M, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000; 132: 425-434.
26. Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
27. Eddahibi S, Humbert M, Fadel E, et al. Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 2002; 121: Suppl. 3, 97S-98S.
28. MacLean M. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension. J Lab Clin Med 1999; 134: 105-114.
29. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
30. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76.
31. Gomberg-Maitland M, Huo D, Benza RL, McLaughlin VV, Tapson VF, Barst RJ. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 2007; 26: 732-738.
32. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
33. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 19: 1060.